Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP8 | P22894 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | LDHA | P00338 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.40 |
| ▸ | SRC | P12931 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL536847 | 0.91 | MMP8 (0.56) | MMP8KMT2AMEN1MAPTS1PR4 | |
| Ether SCHEMBL28330463 | 0.86 | MMP8 (0.51) | MMP8KMT2AMEN1MAPTS1PR4 | |
| SCHEMBL12740250 | 0.86 | MMP8 (0.51) | MMP8KMT2AMEN1MAPTS1PR4 | |
| SCHEMBL25376687 | 0.86 | CYP1A2 (0.52) | MMP8KMT2ALMNACYP1A2LDHA | |
| SCHEMBL1275691 | 0.84 | MMP8 (0.70) | MMP8KMT2AMEN1NPC1GAA | |
| SCHEMBL4064086 | 0.83 | MMP8 (0.51) | MMP8KMT2AMEN1MAPTLMNA | |
| SCHEMBL5766034 | 0.83 | MMP8 (0.51) | MMP8KMT2AMEN1LMNAMAPK1 | |
| SCHEMBL8475858 | 0.83 | LMNA (0.51) | MMP8KMT2AMEN1MAPTLMNA | |
| Hydrochloric Acid SCHEMBL10677191 | 0.82 | MMP8 (0.68) | MMP8KMT2AMEN1NPC1GAA | |
| Methane SCHEMBL28306525 | 0.82 | MMP8 (0.68) | MMP8KMT2AMEN1NPC1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109232575-B | Pyrrole [1,2-b ] pyridazine compound or pharmaceutically acceptable salt thereof and application thereof | 中国科学院上海药物研究所 | 2022-01-25 | — | — | CN | disclosed |
| US-10669264-B2 | Process for the preparation of macitentan | LAURUS LABS LIMITED (IN) | 2020-06-02 | — | — | US | disclosed |
| US-20180370954-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF MACITENTAN | Laurus Labs Ltd. (IN) | 2018-12-27 | — | — | US | disclosed |
| WO-2017093903-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF MACITENTAN | LAURUS LABS PRIVATE LIMITED (IN) | 2017-06-08 | — | — | WO | disclosed |
| US-8324232-B2 | 4-pyrimidinesulfamide derivative | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-12-04 | — | — | US | disclosed |
| EP-2190837-B1 | 4-PYRIMIDINESULFAMIDE DERIVATIVE | ACTELION PHARMACEUTICALS LTD (CH) | 2012-08-15 | — | — | EP | disclosed |
| US-20120142716-A1 | 4-PYRIMIDINESULFAMIDE DERIVATIVE | IDORSIA PHARMACEUTICALS LTD (CH) | 2012-06-07 | — | — | US | disclosed |
| EP-1833821-B1 | SULFAMIDES AS ENDOTHELIN RECEPTOR ANTAGONISTS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES | ACTELION PHARMACEUTICALS LTD (CH) | 2011-03-30 | — | — | EP | disclosed |
| US-7868012-B2 | Sulfamides as endothelin receptor antagonists for the treatment of cardiovascular diseases | ACTELION PHARMACEUTICALS, LTD. (CH) | 2011-01-11 | — | — | US | disclosed |
| EP-2190837-A1 | 4-PYRIMIDINESULFAMIDE DERIVATIVE | Actelion Pharmaceuticals Ltd. (CH) | 2010-06-02 | — | — | EP | disclosed |
| WO-2009024906-A1 | 4-PYRIMIDINESULFAMIDE DERIVATIVE | ACTELION PHARMACEUTICALS LTD (CH) | 2009-02-26 | — | — | WO | disclosed |
| EP-1569914-B1 | PYRIMIDINE-SULFAMIDES AND THEIR USE AS ENDOTHELIAN RECEPTOR ANTAGONIST | ACTELION PHARMACEUTICALS LTD (CH) | 2009-02-18 | — | — | EP | disclosed |
| US-7452896-B2 | Pyrimidine-sulfamides and their use as endothelian receptor antagonist | ACTELION PHARMACEUTICALS LTD. (CH) | 2008-11-18 | — | — | US | disclosed |
| US-20080004298-A1 | Sulfamides as Endothelin Receptor Antagonists for the Treatment of Cardiovascular Diseases | ACTELION PHARMACEUTICALS LTD. (CH) | 2008-01-03 | — | — | US | disclosed |
| EP-1833821-A2 | SULFAMIDES AS ENDOTHELIN RECEPTOR ANTAGONISTS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES | Actelion Pharmaceuticals Ltd. (CH) | 2007-09-19 | — | — | EP | disclosed |
| US-20070167472-A1 | 2-Methoxy-ethanesulfamic acid [6-[2-(5-bromo-pyrimidin-2-yloxy)-ethoxy]-5-(2-chloro-5-methoxy-phenoxy)-pyrimidin-4-yl]-amide; vasoconstrictor, mediator of cardiac, renal, endocrine functions; neurotransmitter release, activation of inflammatory cells, fibrosis, cell proliferation and differentiation | ACTELION PHARMACEUTICALS LTD. (CH) | 2007-07-19 | — | — | US | disclosed |
| WO-2006051502-A2 | SULFAMIDES AS ENDOTHELIN RECEPTOR ANTAGONISTS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES | ACTELION PHARMACEUTICALS LTD (CH) | 2006-05-18 | — | — | WO | disclosed |
| EP-1569914-A1 | PYRIMIDINE-SULFAMIDES AND THEIR USE AS ENDOTHELIAN RECEPTOR ANTAGONIST | Actelion Pharmaceuticals Ltd. (CH) | 2005-09-07 | — | — | EP | disclosed |
| WO-2004050640-A1 | PYRIMIDINE-SULFAMIDES AND THEIR USE AS ENDOTHELIAN RECEPTOR ANTAGONIST | ACTELION PHARMACEUTICALS LTD (CH) | 2004-06-17 | — | — | WO | disclosed |
| US-5571449-A | LIQUID CRYSTALS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1996-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142716-A1 | 4-PYRIMIDINESULFAMIDE DERIVATIVE | EDNRB, EDNRA, TBXA2R | MMP8 4285/4885KMT2A 2186/4885MEN1 2127/4885 |
| US-10669264-B2 | Process for the preparation of macitentan | MACO1, MLEC, MPST | MMP8 1184/4885KMT2A 2330/4885MEN1 40/4885 |
| US-20080004298-A1 | Sulfamides as Endothelin Receptor Antagonists for the Treatment of Cardiovascular Diseases | EDNRA, EDNRB, ECE1 | MMP8 3554/4885KMT2A 1382/4885MEN1 3596/4885 |
| US-20180370954-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF MACITENTAN | MACO1, MLEC, MPST | MMP8 1141/4885KMT2A 2039/4885MEN1 41/4885 |
| US-20070167472-A1 | 2-Methoxy-ethanesulfamic acid [6-[2-(5-bromo-pyrimidin-2-yloxy)-ethoxy]-5-(2-chloro-5-methoxy-phenoxy)-pyrimidin-4-yl]-amide; vasoconstrictor, mediator of cardiac, renal, endocrine functions; neurotransmitter release, activation of inflammatory cells, fibrosis, cell proliferation and differentiation | EDNRA, EDNRB, AGTR2 | MMP8 1399/4885KMT2A 2938/4885MEN1 3515/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.